Tryptamine Therapeutics Ltd (typ) Logo

Tryptamine Therapeutics Ltd (TYP)

___:___ · Healthcare
ASX Delayed
Cboe Live

What is live streaming pricing?

Stock prices will auto-update without reloading the page. How it works:

  • Flashing prices signify an increase (green) or decrease (red) from previous price. Otherwise, price is unchanged.
  • Expect a short delay while pricing data initially loads.
  • Note, prices only update during market hours (10am-4:13pm AEST).

More about Cboe Live pricing.

OK, got it
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials
News

TYP ASX Chart

Snapshot

Tryptamine Therapeutics Limited (TYP, formerly Exopharm Limited) is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy.

Share Price Activity (ASX)

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2025 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) +225.07%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,211 of 2,349
Sector Rank 105 of 231

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies IDT / ATH / ADO
EPS -$0.038
DPS $0.00
Book Value Per Share $0.004

Broker Consensus

TYP is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Price Sensitive only

Corporate Overview

Corporate Details

Head Office Camberwell VIC 3124
Website www.tryptherapeutics.com
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 18 Dec 2018

Upcoming Calendar (Forecasted)

Date Event
25/02/2025 Report (Interim)
29/08/2025 Report (Prelim)
29/09/2025 Report (Prelim)
29/09/2025 Report (Annual)

Former Company Names

  • Exopharm Limited (EX1), 03/05/2024

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors

Management

Director Transactions

TYP directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
16/01/25 Mark Davies Expiry 2,000,000 $0.038 $76,000 Options expired
16/01/25 Jason Carroll Expiry 4,500,000 $0.038 $171,000 Options expired
16/01/25 Gage Jull Expiry 1,000,000 $0.038 $38,000 Options expired
16/01/25 Christopher Ntoumenopoulos Expiry 3,500,000 $0.038 $133,000 Options expired
02/12/24 Jason Carroll Issued 20,250,000 $0.048 $972,000 Issue of options
02/12/24 Christopher Ntoumenopoulos Issued 15,750,000 $0.048 $756,000 Issue of options
02/12/24 Mark Davies Issued 9,000,000 $0.048 $432,000 Issue of options
02/12/24 Gage Jull Issued 1,000,000 $0.048 $48,000 Issue of options
02/10/24 Jason Carroll Buy +550,000 $0.018 $9,900 On-market trade
14/06/24 Jason Carroll Buy +604,738 $0.02 $11,990 On-market trade
06/06/24 Jason Carroll Buy +1,692,514 $0.021 $36,090 On-market trade
05/06/24 Jason Carroll Buy +952,748 $0.022 $20,960 On-market trade
03/06/24 Jason Carroll Buy +1,000,000 $0.025 $25,000 On-market trade
30/05/24 Jason Carroll Buy +500,000 $0.024 $12,000 On-market trade
29/05/24 Jason Carroll Buy +2,000,000 $0.025 $50,000 On-market trade
01/05/24 Mark Davies Issued 2,000,000 $0.02 $40,000 As advised by the company
01/05/24 Clarke Barlow Issued 500,000 $0.02 $10,000 As advised by the company

Director Interests

The current holdings of TYP directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Gage Jull 16/01/2025 1,677,205 1,677,205 10,124,800 N/A
Jason Carroll 16/01/2025 37,300,000 36,750,000 63,642,190 N/A
Mark Davies 16/01/2025 0 2,000,000 11,000,000 N/A
Christopher Ntoumenopoulos 16/01/2025 N/A 6,250,000 34,046,580 N/A
Daniel Tillett 08/11/2024 12,000,000 N/A N/A N/A
Ian Dixon 01/05/2024 N/A 11,303,451 N/A N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 21, 2024.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dr William James Garner 138,467,200 12.16%
Citicorp Nominees Pty Limited 121,484,217 10.67%
William J Garner 47,731,200 4.19%
Mr Jason Alan Carroll 36,750,000 3.23%
James Kuo 21,696,000 1.91%
BNP Paribas Nominees Pty Ltd (Clearstream) 21,287,630 1.87%
Sp Capital Pty Ltd 19,000,000 1.67%
Herwig Janssen 12,500,000 1.10%
Herwig Janssen i 12,500,000 1.10%
Ludwig Criel 12,500,000 1.10%
Ludwig Criel i 12,500,000 1.10%
Morgan Stanley Smith Barney Llc 11,379,118 1.00%
Altnia Holdings Pty Ltd (I Dixon Family A/C) 11,303,451 0.99%
Hsbc Custody Nominees (Australia) Limited A/C 2 10,034,166 0.88%
Solequest Pty Ltd 9,000,000 0.79%
Peterlyn Pty Ltd (Rpc Salmon Super Fund A/C) 8,375,000 0.74%
Computershare Investor Services Inc (Unexchanged Tryp Shares A/C) 8,183,005 0.72%
Kyriaco Barber Pty Ltd 7,575,023 0.67%
Ice Lake Investments Pty Ltd 7,560,128 0.66%
Grayhawk Capital Pty Ltd 7,500,000 0.66%
Valorem Capital Pty Ltd 7,500,000 0.66%
Levent Corporation Pty Ltd Levent Corporation Sf A/C> 7,400,000 0.65%
Grayhawk Capital Pty Ltd i 7,000,000 0.61%
BNP Paribas Noms Pty Ltd 6,743,944 0.59%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 443 561 250 538 648 2,440

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.

Name Last Notice Total Shares Shares Held (%)
William Garner 21/08/2024 198,926,720 17.47

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
01-05-24 William Garner 198,926,720 -- 17.47

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
01-05-24 Ian E Dixon 28,258,627 6.43 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2024 $0.021 28 June
2023 $0.008 30 June
2022 $0.13 30 June
2021 $0.56 30 June
2020 $0.25 30 June
2019 $0.41 28 June
TYP Historical Price Data (CSV)
Up to 20 years of EOD share price history

Important note:

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)

Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.